版本:
中国

BRIEF-Amag says first patient enrolled in phase 2b/3a digoxin immune fab study

June 1 Amag Pharmaceuticals Inc

* Amag announces first patient enrolled in phase 2b/3a digoxin immune fab study conducted by velo bio

* Amag pharmaceuticals -believes results of dif study may form basis for new drug application with potential approval by u.s. Fda in 2020, assuming submission in 2019 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐